Multiple Sclerosis – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Multiple Sclerosis – Pipeline Review, H2 2017’, provides an overview of the Multiple Sclerosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Multiple Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Multiple Sclerosis

The report reviews pipeline therapeutics for Multiple Sclerosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Multiple Sclerosis therapeutics and enlists all their major and minor projects

The report assesses Multiple Sclerosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Multiple Sclerosis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Multiple Sclerosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Multiple Sclerosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

2-BBB Medicines BV

4D Pharma PLC

AB Science SA

AbbVie Inc

Abion Inc

Ablynx NV

Abzena Plc

Acorda Therapeutics Inc

Actelion Pharmaceuticals Ltd

Addex Therapeutics Ltd

Adhaere Pharmaceuticals Inc

Aegis Therapeutics LLC

Affectis Pharmaceuticals AG

AiCuris GmbH & Co KG

Alkermes Plc

Allergan Plc

Alpha Cancer Technologies Inc

Amarna Therapeutics BV

Anavex Life Sciences Corp

Antisense Therapeutics Ltd

Antoxis Ltd

Aphios Corp

Apitope International NV

ARA Healthcare Pvt Ltd

Arrien Pharmaceuticals LLC

Artielle ImmunoTherapeutics Inc

Arven Ilac

AstraZeneca Plc

Atara Biotherapeutics Inc

Athersys Inc

Atlantic Bio Sci LLC

Axxam SpA

Baliopharm AG

Bio-Cancer Treatment International Ltd

BioApex sro

Biocad

Biocon Ltd

Biogen Inc

BioHealthonomics Inc

Bionovis SA

Bionure Farma SL

Biovista Inc

Bolder Biotechnology Inc

BrainStorm Cell Therapeutics Inc

Bristol-Myers Squibb Co

BTB Pharma AB

CASI Pharmaceuticals Inc

Celgene Corp

Cell Cure Neurosciences Ltd

Cell2B Advanced Therapeutics SA

Cinnagen Co

Cognosci Inc

Coherus BioSciences Inc

Commence Bio Inc

Complement Pharma BV

Compugen Ltd

Critical Outcome Technologies Inc

CuraVac Inc

Cyxone AB

DanDrit Biotech A/S

Denceptor Therapeutics Ltd

Eli Lilly and Co

Evgen Pharma Plc

Evotec AG

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

Flex Pharma Inc

Forward Pharma AS

FPRT Bio Inc

Gemac SA

Genervon Biopharmaceuticals LLC

GeNeuro SA

Genzyme Corp

Gilead Sciences Inc

GlaxoSmithKline Plc

Glialogix Inc

Gliknik Inc

Hansa Medical AB

Harbor Therapeutics Inc

Humanigen Inc

Immune Response BioPharma Inc

ImmuneTarget Inc

Immungenetics AG

Immunwork Inc

Inception Sciences Inc

Inovio Pharmaceuticals Inc

Io Therapeutics Inc

Istesso Ltd

Johnson & Johnson

Jyant Technologies Inc

Kadimastem Ltd

Kadmon Corp LLC

KAHR medical Ltd

Karo Pharma AB

Karyopharm Therapeutics Inc

Kissei Pharmaceutical Co Ltd

KPI Therapeutics Inc

Kyorin Pharmaceutical Co Ltd

Lead Discovery Center GmbH

LFB SA

Lipocure Ltd

Longevity Biotech Inc

MacroGenics Inc

Mapi Pharma Ltd

Maruho Co Ltd

MedAnnex Ltd

MedDay SA

Medestea Research & Production SpA

MedImmune LLC

Merck KGaA

Meta-IQ ApS

Mitochon Pharmaceuticals Inc

Mitotech SA

Mitsubishi Tanabe Pharma Corp

Mochida Pharmaceutical Co Ltd

Momenta Pharmaceuticals Inc

MorphoSys AG

Mount Tam Biotechnologies Inc

Neuren Pharmaceuticals Ltd

Neurofx Inc

Neuronax SAS

New World Laboratories Inc

Novartis AG

Nuevolution AB

Numab Innovation AG

Ogeda SA

Omeros Corp

OncoImmune Inc

Oryzon Genomics SA

OSE Immunotherapeutics

Pangen Biotech Inc.

Parvus Therapeutics Inc

Pfenex Inc

Pfizer Inc

Pharmaxis Ltd

Principia Biopharma Inc

ProNoxis AB

Quimatryx SL

ReceptoPharm Inc

RedHill Biopharma Ltd

RegeneRx Biopharmaceuticals Inc

Renovo Neural Inc

Resverlogix Corp

ReveraGen BioPharma Inc

Rhizen Pharmaceuticals SA

Rigel Pharmaceuticals Inc

Rodos BioTarget GmbH

Rubius Therapeutics Inc

SanBio Inc

Santhera Pharmaceuticals Holding AG

Sareum Holdings Plc

Senju Pharmaceutical Co Ltd

Sorrento Therapeutics Inc

Synthon Holdings BV

Teikoku Pharma USA Inc

Teva Pharmaceutical Industries Ltd

TikoMed AB

Tiziana Life Sciences Plc

Toleranzia AB

TolerogenixX GmbH

Topas Therapeutics GmbH

TxCell SA

Vaccinex Inc

Vakzine Projekt Management GmbH

Vicore Pharma AB

viDA Therapeutics Inc

Yeda Research and Development Company Ltd

Yungjin Pharm Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 8

Multiple Sclerosis Overview 9

Multiple Sclerosis Therapeutics Development 10

Multiple Sclerosis Therapeutics Assessment 47

Multiple Sclerosis Companies Involved in Therapeutics Development 69

Multiple Sclerosis Drug Profiles 141

Multiple Sclerosis Dormant Projects 717

Multiple Sclerosis Discontinued Products 735

Multiple Sclerosis Product Development Milestones 738

Appendix 747

List of Tables

List of Tables

Number of Products under Development for Multiple Sclerosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..9), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..10), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..11), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Products under Development by Companies, H2 2017 (Contd..6), H2 2017

Products under Development by Companies, H2 2017 (Contd..7), H2 2017

Products under Development by Companies, H2 2017 (Contd..8), H2 2017

Products under Development by Companies, H2 2017 (Contd..9), H2 2017

Products under Development by Companies, H2 2017 (Contd..10), H2 2017

Products under Development by Companies, H2 2017 (Contd..11), H2 2017

Products under Development by Companies, H2 2017 (Contd..12), H2 2017

Products under Development by Companies, H2 2017 (Contd..13), H2 2017

Products under Development by Companies, H2 2017 (Contd..14), H2 2017

Products under Development by Companies, H2 2017 (Contd..15), H2 2017

Products under Development by Universities/Institutes, H2 2017

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..7), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..6), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..7), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Multiple Sclerosis Pipeline by 2-BBB Medicines BV, H2 2017

Multiple Sclerosis Pipeline by 4D Pharma PLC, H2 2017

Multiple Sclerosis Pipeline by AB Science SA, H2 2017

Multiple Sclerosis Pipeline by AbbVie Inc, H2 2017

Multiple Sclerosis Pipeline by Abion Inc, H2 2017

Multiple Sclerosis Pipeline by Ablynx NV, H2 2017

Multiple Sclerosis Pipeline by Abzena Plc, H2 2017

Multiple Sclerosis Pipeline by Acorda Therapeutics Inc, H2 2017

Multiple Sclerosis Pipeline by Actelion Pharmaceuticals Ltd, H2 2017

Multiple Sclerosis Pipeline by Addex Therapeutics Ltd, H2 2017

Multiple Sclerosis Pipeline by Adhaere Pharmaceuticals Inc, H2 2017

Multiple Sclerosis Pipeline by Aegis Therapeutics LLC, H2 2017

Multiple Sclerosis Pipeline by Affectis Pharmaceuticals AG, H2 2017

Multiple Sclerosis Pipeline by AiCuris GmbH & Co KG, H2 2017

Multiple Sclerosis Pipeline by Alkermes Plc, H2 2017

Multiple Sclerosis Pipeline by Allergan Plc, H2 2017

Multiple Sclerosis Pipeline by Alpha Cancer Technologies Inc, H2 2017

Multiple Sclerosis Pipeline by Amarna Therapeutics BV, H2 2017

Multiple Sclerosis Pipeline by Anavex Life Sciences Corp, H2 2017

Multiple Sclerosis Pipeline by Antisense Therapeutics Ltd, H2 2017

Multiple Sclerosis Pipeline by Antoxis Ltd, H2 2017

List of Figures

List of Figures

Number of Products under Development for Multiple Sclerosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports